TEPLIZUMAB

Teplizumab is an antiCD3 monoclonal antibody that modulates Tcell activity, used to delay type 1 diabetes onset. Side effects include rash, cytokinerelease symptoms, lymphopenia, and infection risk. Only GMP materials will be supplied, logistics all according to GDP.

SKU: c9c06fdaa0bd Category: Tag:

Product Description


Mechanism of Action

TEPLIZUMAB exhibits a highly distributed biochemical activity matrix spanning multiaxis signalling disruption, enzymaticcascade interference, mitochondrialnetwork recalibration, cytoskeletal remodelling, redoxsystem modulation, ionflux redistribution and transcriptionfactor pathway realignment. Its conformational topology enables interaction with catalytic cores, allosteric domains, transmembrane helices, hydrophobic receptor cavities, nucleotidebinding pockets and multiprotein scaffolding structures. This generates systemwide modulation across metabolic, genomic, structural and electrophysiological domains.

At the signalling level, TEPLIZUMAB may reshape phosphorylation gradients, modify propagation dynamics across MAPK/ERK/JNK/p38 axes, alter PI3KAKT survival signalling, shift Gprotein coupling states, recalibrate intracellular Ca²⁺ microdomains, and modulate IP/DAG and cAMPPKA signalling amplitudes. Mitochondrial effects include ETCcomplex rebalancing, ATPturnover adjustment, ROSleakage threshold modulation and membranepotential polarity shifts. Its multinode regulation enables deep experimental interrogation of stressadaptation pathways and metabolicresponse thresholds.

HighResolution

  • Ultrascale kinome interference mapping & catalyticcascade simulation
  • Highfidelity receptorligand docking & conformationalflow modelling
  • Organelle crosstalk modelling (UPR, mitochondrial/ER stress, mitophagy dynamics)
  • Multiomics regulatorynetwork reconstruction (RNAseq, metabolomics, proteomics, phosphoproteomics)
  • Advanced cytoskeletal biomechanics (actin/tubulin turnover, tensionmapping)
  • Cellfate modelling across apoptosis, necroptosis, ferroptosis, parthanatos & autophagic flux axes
  • AIenhanced SAR/QSAR molecularperformance prediction

Toxicodynamics & Hazard Profile

  • Accelerated ROS accumulation & antioxidant-system saturation
  • Mitochondrial fragmentation or ETCchain destabilisation
  • Severe Ca²⁺/Na⁺/K⁺ ionic-flux dysregulation
  • Cytoskeletal depolymerisation & loss of mechanical integrity
  • Membrane damage, permeability shifts & lipidbilayer thinning
  • Inflammatory overactivation via NF-κB, STAT & IRF signalling
  • Multiple programmed-cell-death pathway activation
  • Epigenetic distortions (methylation drift, acetylation imbalance)

For expert laboratory research only not intended for biological exposure.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C2686H4096N724O781S20

Molecular Weight

145000.0 g/mol

CAS Number

907-91-1

Storage Condition

Store at 2-8°C

Solubility

Soluble in water

Purity

Purity information is available upon request (COA).

Synonym

Teplizumab; MGA-031; 876387-05-2

IUPAC/Chemical Name

Anti-CD3ε monoclonal antibody

InChl Key

Unavailable

InChl Code

Unavailable

References

PubChem; ChemBL; FDA;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download